Adjuvanticity and protective immunity elicited by Leishmania donovani antigens encapsulated in positively charged liposomes

Infection and Immunity

Volumn 65, Issue 6, 1997, Pages 2371-2377

  Afrin, Farhat ^a   Ali, Nahid ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOSOME;

ANTIBODY RESPONSE; ANTIGEN RECOGNITION; ARTICLE; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION PREVENTION; INFECTION RESISTANCE; LEISHMANIA DONOVANI; NONHUMAN; PRIORITY JOURNAL;

EID: 0030976397     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.65.6.2371-2377.1997     Document Type: Article

References (58)

1. Afonso, L. C. C., T. M. Scharton, L. Q. Vieira, M. Wysocka, G. Trinchieri, and P. Scott. 1994. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 263:235-237.
2. Ali, N., and F. Afrin. 1997. Protection of mice against visceral leishmaniasis by immunization with promastigote antigen incorporated in liposomes. J. Parasitol. 83:70-75.
3. Basak, S. K., B. Saha, A. Bhattacharya, and S. Roy. 1992. Immunobiological studies on experimental visceral leishmaniasis. II. Adherent cell-mediated down-regulation of delayed-type hypersensitivity response and up-regulation of B cell activation. Eur. J. Immunol. 22:2041-2045.
4. Blackwell, J. M., and O. M. Ulczak. 1984. Immunoregulation of genetically controlled acquired responses to Leishmania donovani infection in mice: demonstration and characterization of suppressor T cells in noncure mice. Infect. Immun. 44:97-102.
5. Bradley, D. J. 1987. Genetics of susceptibility and resistance in the vertebrate host, p. 551-581. In W. Peters and R. Killick-Kendrick (ed.), The leishmaniasis in biology and medicine, vol. 2. Academic Press, London, United Kingdom.
6. Bretscher, P. A., G. Wei, J. N. Menon, and H. Bielefeldt-Ohmann. 1992. Establishment of cell-mediated immunity that makes "susceptible" mice resistant to Leishmania major. Science 257:539-542.
7. Burns, J. M., Jr., W. G. Shreffler, D. R. Benson, H. W. Ghalib, R. Badaro, and S. G. Reed. 1993. Molecular characterization of a kinesin-related antigen of Leishmania chagasi that detects specific antibody in African and American visceral leishmaniasis. Proc. Natl. Acad. Sci. USA 90:775-779.
8. Carvalho, E. M., R. Badaro, S. G. Reed, T. C. Jones, and W. D. Johnson, Jr. 1985. Absence of gamma interferon and interleukin-2 production during active visceral leishmaniasis. J. Clin. Invest. 76:2066-2069.
9. Champsi, J., and D. McMahon-Pratt. 1988. Membrane glycoproiein M-2 protects against Leishmania amazonensis infection. Infect. Immun. 52:3272-3279.
10. Connell, N. D., E. Medina-Acosta, W. R. McMaster, B. K. Bloom, and D. G. Russell. 1993. Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette-Guerin expressing the Leishmania surface proteinase gp63. Proc. Natl. Acad. Sci. USA 90:11473-11477.
11. Deplazes, P., N. C. Smith, P. Arnold, H. Lutz, and J. Eckert. 1995. Specific IgG1 and IgG2 antibody responses of dogs to Leishmania infantum and other parasites. Parasite Immunol. 17:451-458.
12. Evans, T. G., M. J. Teixeira, I. T. McAuliffe, A. W. Vasconcelos, A. Q. Sousa, J. W. Lima, and R. D. Pearson. 1992. Epidemiology of visceral leishmaniasis in northeast Brazil. J. Infect. Dis. 166:1124-1132.
13. Fries, L. F., D. M. Gordon, R. L. Richards, J. E. Egan, M. R. Hollingdale, M. Gross, C. Silverman, and C. R. Alving. 1992. Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy. Proc. Natl. Acad. Sci. USA 89:358-362.
14. Chose, A. C., J. P. Haldar, S. C. Pal, B. P. Mishra, and K. K. Mishra. 1980. Serological investigations on Indian kala-azar. Clin. Exp. Immunol. 40:318-326.
15. Ghosh, A. K., F. K. Bhattacharya, and D. K. Ghosh. 1985. Leishmania donovani: amastigote inhibition and mode of action against berberine. Exp. Parasitol. 60:404-413.
16. Green, M. S., J. D. Kark, C. L. Greenblatt, M. V. Londner, S. Frankenburg, and R. L. Jacobson. 1983. The cellular and humoral immune responses in subjects vaccinated against cutaneous leishmaniasis using Leishmania tropica major promastigotes. Parasite Immunol. 5:337-344.
17. Haldar, J. P., S. Ghose, K. C. Saha, and A. C. Ghose. 1983. Cell-mediated immune response in Indian kala-azar and post kala-azar dermal leishmaniasis. Infect. Immun. 42:702-707.
18. + lymphocytes vivo during healing and progressive murine leishmaniasis. Proc. Natl. Acad. Sci. USA 88:7011-7015.
19. Ho, J. L., R. Badaro, A. Schwartz, C. A. Dinarello, J. A. Gelfand, J. Sobel, A. Barrel, M. B. Netto, E. M. Carvalho, S. G. Reed, and W. D. Johnson, Jr. 1992. Diminished in vitro production of interleukin-1 and tumor necrosis factor-α during acute visceral leishmaniasis and recover after therapy. J. Infect. Dis. 165:1094-1102.
20. Holaday, B. J., M. Pompeii, T. Evans, D. Braga, M. Texeira, A. Sousa, M. Sadick, J. Abrams, R. Pearson, and R. Locksley. 1993. Correlates of Leishmania-specific immunity in the clinical spectrum of infection with Leishmania chagasi. J. Infect. Dis. 167:411-417.
21. Holbrook, J. W., and J. A. Cook. 1983. Immunization of mice against Leishmania donovani by subcutaneous injections of dead promastigotes. Am. J. Trop. Med. Hyg. 32:51-53.
22. Holbrook, J. W., J. A. Cook, and B. W. Parker. 1981. Immunization against Leishmania donovani: glucan as an adjuvant with killed promastigotes. Am. J. Trop. Med. Hyg. 30:762-768.
23. Jaffe, C. L., N. Rachamim, and R. Sarfstein. 1990. Characterization of two proteins from Leishmania donovani and their use for vaccination against visceral leishmaniasis. J. Immunol. 144:699-706.
24. Kahl, L. P., C. A. Scott, R. Lelchuk, G. Gregoriadis, and R. Y. Liew. 1989. Vaccination against murine cutaneous leishmaniasis by using Leishmania major antigen/liposomes. Optimization and assessment of the requirement for intravenous immunization. J. Immunol. 142:4444-4449.
25. Karp, C. L., S. H. El-Safi, T. A. Wynn, M. M. H. Satti, A. M. Kordofani, F. A. Hashim, M. Hag-Ali, F. A. Neva, T. B. Nutman, and D. L. Sacks. 1993. In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin 10 and interferon gamma. J. Clin. Invest. 91:1644-1648.
26. Kaye, P. M., and G. J. Bancroft. 1992. Leishmania donovani infection in scid mice: lack of tissue response and in vivo macrophage activation correlates with failure to trigger natural killer cell-derived gamma interferon production in vitro. Infect. Immun. 60:4335-4342.
27. Kaye, P. M., A. J. Curry, and J. M. Blackwell. 1991. Differential production of Th-1 and Th-2 derived cytokines does not determine the genetically controlled or vaccine induced rate of cure in murine visceral leishmaniasis. J. Immunol. 146:2763-2770.
28. Kemp, M., J. A. Kurtzhals, K. Bendtzen, L. K. Pouben, H. B. Hansen, D. K. Koech, A. Kharazmi, and T. G. Theander. 1993. Leishmania donovani reactive Th1- and Th2-like T-cell clones from individuals who have recovered. from visceral leishmaniasis. Infect. Immun. 61:1069-1073.
29. Kemp, M., J. A. Kurtzhals, C. B. V. Christensen, A. Kharazmi, A. Jardim, K. Bendtzen, G. S. Gachihi, K. W. Olafson, and T. G. Theander. 1993. Production of Interferon gamma and interleukin-4 by human T cells recognizing Leshmania donovani lipophosphoglycan-associated protein. Immunol. Lett. 38:137-144.
30. + T cells in intracellular infections in humans: leishmaniasis as an example. Immunol. Today 17:13-16.
31. Krowka, J., D. Stites, R. Debs, C. Larsen, J. Fedor, E. Brunette, and N. Duzgunes. 1990. Lymphocyte proliferative responses to soluble and liposome-conjugatcd envelope peptides of HIV-1. J. Immunol. 144:2535-2540.
32. Latif, N., and B. K. Bachhawat. 1984. The effect of surface charges of liposomes in immunopotentiation. Biosci. Rep. 4:99-107.
33. Latif, N. A., and C. Mandal. 1987. Liposome as an adjuvant for the production of estradiol antibodies. Immunol. Lett. 15:237-242.
34. Lowry, O. H., N. J. Rosebrough, A. L. Farr, and R. J. Randall. 1951. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:265-275.
35. Maybrink, W., P. Williams, C. A. da Costa, P. A. Magalhaes, M. N. Melo, M. Dias, A. O. Lima, M. S. M. Michalick, E. F. Carvalho, G. C. Barros, P. A. Sessa, and J. T. A. de Alencar. 1985. An experimental vaccine against American dermal leishmaniasis: experience in the state of Espirito Santo, Brazil. Ann. Trop. Med. Parasitol. 79:259-269.
36. Melby, P. C., F. J. Andrade-Narvaez, B. J. Darnell, G. Valencia-Pacheco, V. V. Tryon, and A. Palomo-Cetina. 1994. Increased expression of proinflammatory cytokines in chronic lesions of human cutaneous leishmaniasis. Infect. Immun. 62:837-842.
37. Meller-Melloul, C., C. Farnarier, S. Dunan, B. Faugere, J. Franck, C. Mary, P. Bongrand, M. Quilici, and S. Kaplanski. 1991. Evidence of subjects sensitized to Leishmania infantum on the French Mediterranean coast: differences in gamma interferon production between this population and visceral leishmaniasis patients. Parasite Immunol. 13:531-536.
38. Miralles, G. D., M. Y. Stoeckle, D. F. McDermott, F. D. Finkelman, and H. W. Murray. 1994. Th1 and Th2 cell-associated cytokines in experimental visceral leishmaniasis. Infect. Immun. 62:1058-1063.
39. Modabber, F. 1989. Experience with vaccines against cutaneous leishmaniasis of men and mice. Parasitology 98:549-560.
40. Muller, I., T. Pedrozzini, J. P. Farrell, and J. Louis. 1989. T-cell responses and immunity to experimental infection with Leishmania major. Ann. Rev. Immunol. 7:561-578.
41. Murray, H. W., K. E. Squires, C. D. Miralles, M. Y. Stoeckle, A. M. Granger, A. Granelli-Piperno, and C. Bogdan. 1992. Acquired resistance and granuloma formation in experimental visceral leishmaniasis. Differential T cell and lymphokine roles in initial versus established immunity. J. Immunol. 148:1858-1863.
42. Rachamim, N., and C. L. Jaffe. 1993. Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis. J. Immunol. 150:2322-2331.
43. Reddy, R., F. Zhou, S. Nair, L. Huang, and B. T. Rouse. 1992. In vivo cytotoxic T lymphocyte induction with soluble proteins administered in liposomes. J. Immunol. 148:1585-1589.
44. Reiner, N. E. 1982. Host-parasite relationship in murine leishmaniasis: pathophysiological and immunological changes. Infect. Immun. 38:1223-1230.
45. Rivier, D., R. Shah, P. Bovay, and J. Mauel. 1993. Vaccine development against cutaneous leishmaniasis. Subcutaneous administration of radio-attenuated parasites protects CBA mice against virulent Leishmania major challenge. Parasite Immunol. 15:74-84.
46. Russel, D. G., and J. Alexander. 1988. Effective immunization against cutaneous leishmaniasis with defined membrane antigens reconstituted into liposomes. J. Immunol. 140:1274-1279.
47. Scott, P. 1989, The role of Th1 and Th2 cells in experimental cutaneous leishmaniasis. Exp. Parasitol. 68:369-372.
48. Scott, P., P. Caspar, and A. Sher. 1990. Protection against Leishmania major in BALB/c mice by adoptive transfer of a T cell clone recognizing a low molecular weight antigen released by promastigotes. J. Immunol. 144:1075-1079.
49. Scott, P., E. Pearce, P. Natovitz, and A. Sher. 1987. Vaccination against cutaneous leishmaniasis in a murine model. 1. Induction of protective immunity with a soluble extract of promastigotes. J. Immunol. 139:221-227.
50. Snapper, C. M., and W. E. Paul. 1987. Interferon and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science 236:944-947.
51. Stauber, L. A., E. M. Franchino, and J. Grun. 1958. An eight day method for screening compounds against Leishmania donovani in the golden hamster. J. Protozool. 5:269-273.
52. + cells in experimental visceral leishmaniasis. J. Immunol. 140:3971-3977.
53. Titus, R. G., F. Gueiros-Filho, L. A. R. de Freitas, and S. M. Beverly. 1995. Development of a safe live Leishmania vaccine line by gene replacement. Proc. Natl. Acad. Sci. USA 92:10267-10271.
54. Titus, R. G., G. C. Lima, H. D. Engers, and J. A. Louis. 1984. Exacerbation of murinc cutaneous leishmaniasis by adoptive transfer of parasite-specific helper T cell populations capable of mediating Leishmania major-specific delayed-type hypersensitivity. J. Immunol. 133:1594-1600.
55. White, A. C., Jr., and D. McMahon-Pratt. 1990, Prophylactic immunization against experimental Leishmania donovani infection by use of a purified protein vaccine. J. Infect. Dis. 161:1313.
56. Wilson, M. E., B. M. Young, K. P. Andersen, J. V. Weinstock, A. Metwali, K. M. Ali, and J. E. Donelson. 1995. A recombinant Leishmania chagasi antigen that stimulates cellular immune responses in infected mice. Infect. Immun. 63:2062-2069.
57. -). Immunology 85:1-7.
58. Yang, D. M., M. V. Rogers, and F. Y. Liew. 1991. Identification and characterization of host-protective T-cell epitopes of a major surface glycoprotein (gp63) from Leishmania major. Immunology 72:3-9.